Free press releases distribution network?

Agency / Source: Nano Bridging Molecules S.A

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Nano Bridging Molecules SA Announces Successful Conclusion of its Second Round Financing - Nano Bridging Molecules S.A (NBM), a Swiss early stage med-tech company devoted to developing new generation medical implant surface modifications, announced the successful conclusion of the second of three planned financing rounds
Nano Bridging Molecules SA Announces Successful Conclusion of its Second Round Financing

 

PRZOOM - /newswire/ - Gland, Switzerland, 2009/08/17 - Nano Bridging Molecules S.A (NBM), a Swiss early stage med-tech company devoted to developing new generation medical implant surface modifications, announced the successful conclusion of the second of three planned financing rounds.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Following oversubscription of the company’s first funding round in 2007 NBM significantly expanded its pre-clinical testing program, embarked on its first dental human clinical trial, recruited key scientific and clinical research staff and relocated its operations to purpose built laboratories and new offices in the Swiss canton of Vaud. Notwithstanding the current economic downturn the company has fully subscribed its second funding round. The funds raised are being used to conclude a 52 week large animal pre-clinical study (one of the largest of its kind conducted in Switzerland), commencement of orthopedic pre-clinical studies and expansion of its ongoing human dental clinical trials with the establishment of additional study centers in each of Europe and the US. The company is working closely with regulatory consultants aiming to have its first CE Marked dental implant surface treatment on the market in Q4 2010 and to achieve first sales in the orthopedics area in 2012.

About Nano Bridging Molecules S.A.

NBM (nbmolecules.com) is an award winning company which owns the global rights to develop, manufacture and market its SurfLink® technology. At the heart of this technology are patented multi-phosphonated molecules which have been developed over a twelve year period by world-leading, multi-disciplinary scientific teams from the University of Geneva and Ecole Polytechnique Fédérale de Lausanne.

Presently patients requiring joint replacement or spinal implant surgery are required to wait for as long as they possibly can before being operated on as a direct consequence of the limited life span of today’s devices and the likelihood they will, at some point, need to be replaced. Covalently bound to implant surfaces prior to surgery, NBM’s SurfLink® molecules facilitate a chemical reaction that naturally fuses treated implant surfaces to the patient’s bone. This gives rise to the exciting prospect of patients, regardless of age, being able to receive SurfLink® treated implants which will provide truly long term if not a lifetime of service.

For more information please contact:
Björn-Owe Aronsson, a founder and CTO for scientific or technical information
T: +41 (0) 22 354 0054 - E: bjorn-owe.aronsson[.]nbmolecules.com.

Neville Drower, CAO and General Counsel in respect of commercial, regulatory or legal matters
T: +41 (0) 22 354 0051 - E: neville.drower[.]nbmolecules.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Nano Bridging Molecules S.A

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Nano Bridging Molecules SA Announces Successful Conclusion of its Second Round Financing

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Neville Drower - NBMolecules.com 
+41 22-354-0054 neville.drower[.]nbmolecules.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Nano Bridging Molecules S.A securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Nano Bridging Molecules S.A / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

PleurX™ Catheter System Receives FDA 510(k) Clearance for Specific Non-Malignant Recurrent Pleural Effusions
Greenphire and Exostar Partner to Deliver Seamless, Secure Access to Clinical Research Site Payment Solution
First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  Intrinsic Executive Search Ltd

Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today